VERICI DX PLC

Management Reports • Oct 6, 2025

National Storage Mechanism | Additional information

RNS Number : 1660C

Verici Dx PLC

06 October 2025

Verici Dx plc

("Verici Dx" or the "Company")

Update on Tutivia™ test adoption

9 new transplant centres on-boarded

19% increase in ordering clinicians in Q3

Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces positive progress in its plans to drive strong Tutivia™ sales growth following the equity fundraise completed in July.

Commercial scale-up of Tutivia test adoption, a test for acute rejection post transplant, has progressed in Q3, with a 19% increase in ordering clinicians in the quarter, and the addition of nine new centres, making a total of 30 transplant centres now onboarded, representing 16% of annual transplants in the US. Volume growth from this progress is expected from Q4 and the number of orders in Q3 were consistent with the previous two quarters.

The Company has expanded its commercial team with three new senior sales hires. In addition, a Director of Clinical Partnerships will be joining the commercial team in mid-October.

The Board continues to target meeting market expectations for the full year.

Investor presentation

Sara Barrington, Chief Executive Officer, and David Anderson, Chief Financial Officer, will provide a live presentation via the Investor Meet Company platform on 7 October at 10.00 am BST. This presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via:

https://www.investormeetcompany.com/verici-dx-plc/register-investor

Investors who already follow Verici Dx on the Investor Meet Company platform will automatically be invited.

Verici Dx plc	www.vericidx.com
Sara Barrington, CEO	Via Walbrook PR
Singer Capital Markets (Nominated adviser and Joint Broker)		Tel: +44 (0)20 7496 3000
Phil Davies / Sam Butcher
Oberon Capital (Joint Broker)	Tel: +44 (0)20 3179 0500
Mike Seabrook / Adam Pollock
Walbrook PR (Media & Investor Relations)	Tel: +44 (0)20 7933 8780 or [email protected]
Alice Woodings / Paul McManus	Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBELLBEBLBFBL